AP7: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== |
Latest revision as of 19:17, 8 August 2012
WikiDoc Resources for AP7 |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on AP7 at Clinical Trials.gov Clinical Trials on AP7 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on AP7
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating AP7 Risk calculators and risk factors for AP7
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
AP7 is a selective NMDA receptor (NMDAR) antagonist that competitively inhibits the active site of NMDAR. Its chemical name is 2-amino-7-phosphonoheptanoic acid.